Pharmacovigilance Market Size, Share, Trends, Growth 2032
Pharmacovigilance Market By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4), By Service Provider (In-House and Contract Outsourcing), By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining), and By End-User (Hospitals, Research Organizations, and Industries), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 9.20 Billion | USD 18.83 Billion | 8.28% | 2023 |
Table Of Content
- Chapter 1. Introduction
- 1.1. Report description and scope
- 1.2. Research scope
- 1.3. Research methodology
- 1.3.1. Market research process
- 1.3.2. Market research methodology
- Chapter 2. Executive Summary
- 2.1. Global pharmacovigilance market, 2016-2025 (USD Billion)
- 2.2. Global pharmacovigilance market: Snapshot
- Chapter 3. Pharmacovigilance Market - Industry Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Global pharmacovigilance market drivers: impact analysis
- 3.2.2. Increasing consumption of drugs fuels the continuous drug event monitoring demand
- 3.2.3. The rising adoption of outsourcing services
- 3.3. Market Restraints
- 3.3.1. Global pharmacovigilance market restraints: impact analysis
- 3.3.2. High risk associated with data security in pharmacovigilance outsourcing
- 3.4. Opportunities
- 3.4.1. Huge scope for the rapid growth of pharmacovigilance market in emerging economies
- 3.5. Porter's Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis, by clinical trial phase
- 3.6.2. Market attractiveness analysis, by service provider
- 3.6.3. Market attractiveness analysis, by method
- 3.6.4. Market attractiveness analysis, by end-user
- 3.6.5. Market attractiveness analysis, by region
- Chapter 4. Global Pharmacovigilance Market - Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global pharmacovigilance market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New therapy launch
- 4.2.3. Agreements, partnerships, collaborations, and joint ventures
- 4.2.4. Research and development and regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Pharmacovigilance Market - Clinical Trial Phase Analysis
- 5.1. Global pharmacovigilance market: clinical trial phase overview
- 5.1.1. Global pharmacovigilance market revenue share, by clinical trial phase, 2018 and 2025
- 5.2. Pre-Clinical
- 5.2.1. Global pharmacovigilance market for pre-clinical, 2016-2025 (USD Billion)
- 5.3. Phase 1
- 5.3.1. Global pharmacovigilance market for phase 1, 2016-2025 (USD Billion)
- 5.4. Phase 2
- 5.4.1. Global pharmacovigilance market for phase 2, 2016-2025 (USD Billion)
- 5.5. Phase 3
- 5.5.1. Global pharmacovigilance market for phase 3, 2016-2025 (USD Billion)
- 5.6. Phase 4
- 5.6.1. Global pharmacovigilance market for phase 4, 2016-2025 (USD Billion)
- 5.1. Global pharmacovigilance market: clinical trial phase overview
- Chapter 6. Global Pharmacovigilance Market - Service Provider Analysis
- 6.1. Global pharmacovigilance market: service provider overview
- 6.1.1. Global pharmacovigilance market revenue share, by service provider, 2018 and 2025
- 6.2. In-House
- 6.2.1. Global pharmacovigilance market for in-house, 2016-2025 (USD Billion)
- 6.3. Contract Outsourcing
- 6.3.1. Global pharmacovigilance market for contract outsourcing, 2016-2025 (USD Billion)
- 6.1. Global pharmacovigilance market: service provider overview
- Chapter 7. Global Pharmacovigilance Market - Method Analysis
- 7.1. Global pharmacovigilance market: method overview
- 7.1.1. Global pharmacovigilance market revenue share, by method, 2018 and 2025
- 7.2. Spontaneous Reporting
- 7.2.1. Global pharmacovigilance market for spontaneous reporting, 2016-2025 (USD Billion)
- 7.3. Intensified ADR Reporting
- 7.3.1. Global pharmacovigilance market for intensified ADR reporting, 2016-2025 (USD Billion)
- 7.4. Targeted Spontaneous Reporting
- 7.4.1. Global pharmacovigilance market for targeted spontaneous reporting, 2016-2025 (USD Billion)
- 7.5. Cohort Event Monitoring
- 7.5.1. Global pharmacovigilance market for cohort event monitoring, 2016-2025 (USD Billion)
- 7.6. EHR Mining
- 7.6.1. Global pharmacovigilance market for EHR mining, 2016-2025 (USD Billion)
- 7.1. Global pharmacovigilance market: method overview
- Chapter 8. Global Pharmacovigilance Market- End-User Analysis
- 8.1. Global pharmacovigilance market: end-user overview
- 8.1.1. Global pharmacovigilance market revenue share, by end-user, 2018 and 2025
- 8.2. Hospitals
- 8.2.1. Global pharmacovigilance market for hospitals, 2016-2025 (USD Billion)
- 8.3. Research Organizations
- 8.3.1. Global pharmacovigilance market for research organizations, 2016-2025 (USD Billion)
- 8.4. Industries
- 8.4.1. Global pharmacovigilance market for industries, 2016-2025 (USD Billion)
- 8.1. Global pharmacovigilance market: end-user overview
- Chapter 9. Global Pharmacovigilance Market- Regional Analysis
- 9.1. Global pharmacovigilance market: regional overview
- 9.1.1. Global pharmacovigilance market revenue share, by region, 2018 and 2025
- 9.2. North America
- 9.2.1. North America pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.2.2. North America pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.2.3. North America pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.2.4. North America pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.2.5. The U.S.
- 9.2.5.1. The U.S. pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.2.5.2. The U.S. pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.2.5.3. The U.S. pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.2.5.4. The U.S. pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.2.6. Canada
- 9.2.6.1. Canada pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.2.6.2. Canada pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.2.6.3. Canada pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.2.6.4. Canada pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.3. Europe
- 9.3.1. Europe pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.3.2. Europe pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.3.3. Europe pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.3.4. Europe pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.3.5. UK
- 9.3.5.1. UK pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.3.5.2. UK pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.3.5.3. UK pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.3.5.4. UK pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.3.6. Germany
- 9.3.6.1. Germany pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.3.6.2. Germany pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.3.6.3. Germany pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.3.6.4. Germany pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.3.7. France
- 9.3.7.1. France pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.3.7.2. France pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.3.7.3. France pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.3.7.4. France pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.3.8. Rest of Europe
- 9.3.8.1. Rest of Europe pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.3.8.2. Rest of Europe pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.3.8.3. Rest of Europe pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.3.8.4. Rest of Europe pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.4.2. Asia Pacific pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.4.3. Asia Pacific pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.4.4. Asia Pacific pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.4.5. China
- 9.4.5.1. China pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.4.5.2. China pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.4.5.3. China pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.4.5.4. China pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.4.6. Japan
- 9.4.6.1. Japan pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.4.6.2. Japan pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.4.6.3. Japan pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.4.6.4. Japan pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.4.7. India
- 9.4.7.1. India pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.4.7.2. India pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.4.7.3. India pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.4.7.4. India pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.4.8. Rest of Asia Pacific
- 9.4.8.1. Rest of Asia Pacific pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.4.8.2. Rest of Asia Pacific pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.4.8.3. Rest of Asia Pacific pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.4.8.4. Rest of Asia Pacific pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.5. Latin America
- 9.5.1. Latin America pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.5.2. Latin America pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.5.3. Latin America pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.5.4. Latin America pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.5.5. Brazil
- 9.5.5.1. Brazil pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.5.5.2. Brazil pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.5.5.3. Brazil pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.5.5.4. Brazil pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.5.6. Rest of Latin America
- 9.5.6.1. Rest of Latin America pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.5.6.2. Rest of Latin America pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.5.6.3. Rest of Latin America pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.5.6.4. Rest of Latin America pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.6. The Middle East and Africa
- 9.6.1. The Middle East and Africa pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
- 9.6.2. The Middle East and Africa pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
- 9.6.3. The Middle East and Africa pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
- 9.6.4. The Middle East and Africa pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
- 9.1. Global pharmacovigilance market: regional overview
- Chapter 10. Company Profile
- 10.1. F. Hoffmann-La Roche
- 10.1.1. Overview
- 10.1.2. Financials
- 10.1.3. Product portfolio
- 10.1.4. Business strategy
- 10.1.5. Recent developments
- 10.2. Cognizant
- 10.2.1. Overview
- 10.2.2. Financials
- 10.2.3. Product portfolio
- 10.2.4. Business strategy
- 10.2.5. Recent developments
- 10.3. Pharmaceutical Clinical Trial Phase Development
- 10.3.1. Overview
- 10.3.2. Financials
- 10.3.3. Product portfolio
- 10.3.4. Business strategy
- 10.3.5. Recent developments
- 10.4. Bristol-Myers Squibb
- 10.4.1. Overview
- 10.4.2. Financials
- 10.4.3. Product portfolio
- 10.4.4. Business strategy
- 10.4.5. Recent developments
- 10.5. Covance
- 10.5.1. Overview
- 10.5.2. Financials
- 10.5.3. Product portfolio
- 10.5.4. Business strategy
- 10.5.5. Recent developments
- 10.6. ICON
- 10.6.1. Overview
- 10.6.2. Financials
- 10.6.3. Product portfolio
- 10.6.4. Business strategy
- 10.6.5. Recent developments
- 10.7. Accenture
- 10.7.1. Overview
- 10.7.2. Financials
- 10.7.3. Therapy portfolio
- 10.7.4. Business strategy
- 10.7.5. Recent developments
- 10.8. Pfizer
- 10.8.1. Overview
- 10.8.2. Financials
- 10.8.3. Product portfolio
- 10.8.4. Business strategy
- 10.8.5. Recent developments
- 10.9. Clinquest Group
- 10.9.1. Overview
- 10.9.2. Financials
- 10.9.3. Therapy portfolio
- 10.9.4. Business strategy
- 10.9.5. Recent developments
- 10.10. Novartis International
- 10.10.1. Overview
- 10.10.2. Financials
- 10.10.3. Product portfolio
- 10.10.4. Business strategy
- 10.10.5. Recent developments
- 10.11. GlaxoSmithKline
- 10.11.1. Overview
- 10.11.2. Financials
- 10.11.3. Product portfolio
- 10.11.4. Business strategy
- 10.11.5. Recent developments
- 10.12. PAREXEL International
- 10.12.1. Overview
- 10.12.2. Financials
- 10.12.3. Product portfolio
- 10.12.4. Business strategy
- 10.12.5. Recent developments
- 10.13. iGATE Corporation
- 10.13.1. Overview
- 10.13.2. Financials
- 10.13.3. Product portfolio
- 10.13.4. Business strategy
- 10.13.5. Recent developments
- 10.14. iMEDGlobal Corporation
- 10.14.1. Overview
- 10.14.2. Financials
- 10.14.3. Product portfolio
- 10.14.4. Business strategy
- 10.14.5. Recent developments
- 10.15. inVentiv Health
- 10.15.1. Overview
- 10.15.2. Financials
- 10.15.3. Product portfolio
- 10.15.4. Business strategy
- 10.15.5. Recent developments
- 10.1. F. Hoffmann-La Roche
Table Of Figures
List of Figures
1. Market research process
2. Market research methodology
3. Global pharmacovigilance market revenue, 2016–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Pharmacovigilance market attractiveness analysis, by clinical trial phase
6. Pharmacovigilance market attractiveness analysis, by service provider
7. Pharmacovigilance market attractiveness analysis, by method
8. Pharmacovigilance market attractiveness analysis, by end-user
9. Pharmacovigilance market: market attractiveness analysis, by region
10. Company market share analysis, 2018
11. Global pharmacovigilance market revenue share by clinical trial phase, 2018 and 2025
12. Global pharmacovigilance market for pre-clinical, 2016–2025 (USD Billion)
13. Global pharmacovigilance market for phase 1, 2016–2025 (USD Billion)
14. Global pharmacovigilance market for phase 2, 2016–2025 (USD Billion)
15. Global pharmacovigilance market for phase 3, 2016–2025 (USD Billion)
16. Global pharmacovigilance market for phase 4, 2016–2025 (USD Billion)
17. Global pharmacovigilance market revenue share by service provider, 2018 and 2025
18. Global pharmacovigilance market for in-house, 2016–2025 (USD Billion)
19. Global pharmacovigilance market for contract outsourcing, 2016–2025 (USD Billion)
20. Global pharmacovigilance market revenue share by method, 2018 and 2025
21. Global pharmacovigilance market for spontaneous reporting, 2016–2025 (USD Billion)
22. Global pharmacovigilance market for intensified ADR reporting, 2016–2025 (USD Billion)
23. Global pharmacovigilance market for targeted spontaneous reporting, 2016–2025 (USD Billion)
24. Global pharmacovigilance market for cohort event monitoring, 2016–2025 (USD Billion)
25. Global pharmacovigilance market for EHR mining, 2016–2025 (USD Billion)
26. Global pharmacovigilance market revenue share by end-user, 2018 and 2025
27. Global pharmacovigilance market for hospitals, 2016–2025 (USD Billion)
28. Global pharmacovigilance market for research organizations, 2016–2025 (USD Billion)
29. Global pharmacovigilance market for industries, 2016–2025 (USD Billion)
30. Global pharmacovigilance market revenue share by region, 2018 and 2025
31. North America pharmacovigilance market, 2016–2025 (USD Billion)
32. Europe pharmacovigilance market, 2016–2025 (USD Billion)
33. Asia Pacific pharmacovigilance market, 2016–2025 (USD Billion)
34. Latin America pharmacovigilance market, 2016–2025 (USD Billion)
35. The Middle East and Africa pharmacovigilance market, 2016–2025 (USD Billion)
Table Of Tables
List of Tables
1. Pharmacovigilance market: Market Snapshot
2. Drivers of global pharmacovigilance market: impact analysis
3. Restraints of global pharmacovigilance market: impact analysis
4. North America pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
5. North America pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
6. North America pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
7. North America pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
8. The U.S. pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
9. The U.S. pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
10. The U.S. pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
11. The U.S. pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
12. Canada pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
13. Canada pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
14. Canada pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
15. Canada pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
16. Europe pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
17. Europe pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
18. Europe pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
19. Europe pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
20. UK pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
21. UK pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
22. UK pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
23. UK pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
24. Germany pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
25. Germany pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
26. Germany pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
27. Germany pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
28. France pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
29. France pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
30. France pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
31. France pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
32. Rest of Europe pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
33. Rest of Europe pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
34. Rest of Europe pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
35. Rest of Europe pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
36. Asia Pacific pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
37. Asia Pacific pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
38. Asia Pacific pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
39. Asia Pacific pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
40. China pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
41. China pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
42. China pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
43. China pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
44. Japan pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
45. Japan pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
46. Japan pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
47. Japan pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
48. India pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
49. India pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
50. India pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
51. India pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
52. Rest of Asia Pacific pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
53. Rest of Asia Pacific pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
54. Rest of Asia Pacific pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
55. Rest of Asia Pacific pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
56. Latin America pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
57. Latin America pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
58. Latin America pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
59. Latin America pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
60. Brazil pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
61. Brazil pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
62. Brazil pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
63. Brazil pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
64. Rest of Latin America pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
65. Rest of Latin America pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
66. Rest of Latin America pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
67. Rest of Latin America pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
68. The Middle East and Africa pharmacovigilance market revenue, by clinical trial phase, 2016–2025 (USD Billion)
69. The Middle East and Africa pharmacovigilance market revenue, by service providers, 2016–2025 (USD Billion)
70. The Middle East and Africa pharmacovigilance market revenue, by method, 2016–2025 (USD Billion)
71. The Middle East and Africa pharmacovigilance market revenue, by end-user, 2016–2025 (USD Billion)
Methodology
FrequentlyAsked Questions
The science and activities of pharmacovigilance are dedicated to the detection, assessment, comprehension, and prevention of adverse effects or any other drug-related issues. The primary objective of pharmacovigilance is to guarantee the safe and effective use of medications and enhance patient safety.
The demand for robust pharmacovigilance systems to monitor and ensure the safety of new medications and treatments is driven by the growth in pharmaceutical research and development, as well as an increase in clinical trials. The incidence of adverse drug reactions (ADRs) increases in tandem with the number of pharmaceuticals available on the market. This requires the implementation of comprehensive pharmacovigilance practices to mitigate and manage the risks associated with drug therapies.
The global pharmacovigilance market size was worth around USD 9.20 billion in 2023 and is predicted to grow to around USD 18.83 billion by 2032.
The global pharmacovigilance market a compound annual growth rate (CAGR) of roughly 8.28% between 2024 and 2032.
The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., UK, Germany, France, China, Japan, India, Brazil, etc.
Some key players in the global pharmacovigilance market include as F. Hoffmann-La Roche, Cognizant, Pharmaceutical Clinical Trial Phase Development, Bristol-Myers Squibb, Covance, ICON, Accenture, Pfizer, Clinquest Group, Novartis International, GlaxoSmithKline, PAREXEL International, iGATE Corporation, iMEDGlobal Corporation, and inVentiv Health.
HappyClients
